珠海都市网
您当前的位置 :首页 > 文传商讯 > 正文
Galderma Delivers a Strong Start to the Year With Record Net Sales of Over 1 Billion USD for the First Quarter and 12.4% Year-on-Year Growth
2024年04月25日 00:50:20来源:作者:
【摘要】 文传商讯,中国领先的新闻稿来源,由国际文传(中国)电讯社携手美国商业资讯对外提供。帮助美国商业资讯将其客户的新闻稿呈现给大中华区的目标受众,每日提供由国际文传专业记者团队报导的有关这些行业的中文新闻

Ad hoc announcement pursuant to Art. 53 LR

ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024.

  • Record net sales of 1.071 billion USD in the first quarter of 2024, surpassing for the first time the 1 billion USD mark for the first three months in a year
  • Net sales growth for the first quarter of 2024 was 12.4% year-on-year on a constant currency basis1, primarily driven by volume
  • Broad-based growth across all product categories, with constant currency year-on-year growth of 19.3% for Injectable Aesthetics, 8.4% for Dermatological Skincare, and 4.1% for Therapeutic Dermatology
  • Growth across geographies, especially in International markets while U.S. growth accelerated year-on-year
  • 2024 full year guidance confirmed: 7-10% net sales year-on-year growth at constant currency and Core EBITDA margin in line with 2023 at constant currency
  • Continued execution of Galderma’s integrated dermatology strategy, progressing on its innovation pipeline, commercial execution, as well as market-leading education and services
  • Publicly listed as GALD on the SIX Swiss Exchange since March 22, 2024, following the initial public offering

“We started the year strong, continuing on Galderma’s growth trajectory and celebrating our first days of trading on the SIX Swiss Exchange. This is a testament to our proven integrated dermatology strategy and the focus of our employees globally, each committed to serving our healthcare professionals, consumers and patients worldwide. With attractive growth across our product categories and geographies, we are confident in our financial outlook for the year.”

FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA

Strong commercial performance

For the first quarter of 2024, Galderma achieved record net sales of 1.071 billion USD, surpassing the 1 billion USD mark for the first three months in a year for the first time. Year-on-year net sales growth on a constant currency basis for the period was 12.4%, primarily driven by volume.

Net Sales growth was widespread across product categories and geographies. All product categories grew, with notable strong performance in Injectable Aesthetics supported by a low 2023 comparable base. Across International markets, there was continued double-digit growth momentum fueled by strong performance in major markets. For the U.S., growth accelerated year-on-year and was primarily driven by volume and a favorable product mix.

Injectable Aesthetics

Injectable Aesthetics net sales for the first quarter of 2024 were 511 million USD, with year-on-year growth of 19.3% on a constant currency basis.

Both Injectable Aesthetics sub-categories grew double-digit. For the first three months of 2024, Neuromodulators net sales were 263 million USD, with year-on-year growth of 20.4% on a constant currency basis, and Fillers and Biostimulators net sales were 248 million USD, with year-on-year growth of 18.2% on a constant currency basis.

Injectable Aesthetics growth overall was mainly driven by volume, with continued growth momentum across geographies. Year-on-year growth for the first three months of 2024 was supported by a low 2023 comparable base, predominantly for the Fillers & Biostimulators sub-category.

Dermatological Skincare

Dermatological Skincare net sales for the first quarter of 2024 were 351 million USD, with year-on-year growth of 8.4% on a constant currency basis.

The growth overall was mainly driven by volume and favorable product mix. Cetaphil in International markets and Alastin both grew double-digits more than offsetting market softness in the U.S. skincare market and lower U.S. consumption of Cetaphil.

Therapeutic Dermatology

Therapeutic Dermatology net sales for the first quarter of 2024 were 209 million USD, with year-on-year growth of 4.1% on a constant currency basis.

The growth was mainly driven by volume in International markets offsetting anticipated lower US volumes, partially driven by phasing impact, as well as ongoing genericization.

With a strong start to the year, Galderma confirms its full year guidance for 2024, of 7-10% net sales year-on-year growth at constant currency and a Core EBITDA margin in line with 2023 at constant currency.

Galderma’s proven Integrated Dermatology Strategy

The strong momentum is based on continued execution in the first quarter of the year of Galderma’s three strategic pillars, expanding the broadest portfolio in dermatology with leading science and innovation, strengthening commercial execution, and offering market-leading education and services.

Regarding its leading dermatology portfolio, Galderma continued to drive growth through portfolio and geographic expansion. Recent new launches were a strong source of growth, such as Cetaphil’s new ranges including Healthy Renew anti-aging skincare, Sculptra’s launch in Thailand, as well as new product introductions and international expansion for both Alastin and acne brands. Galderma also maintained efforts to strengthen its scientific differentiation as well as advance its innovation pipeline across product categories. This included launching Restylane SHAYPE™ in Canada, a filler with ‘bone-mimicking’ properties using NASHA HD™ technology for temporary augmentation of the chin region, and nemolizumab’s regulatory submission update announcing FDA priority review for prurigo nodularis and regulatory filing acceptance in the U.S. and the EU for both prurigo nodularis and atopic dermatitis.

As for commercial execution, Galderma maintained its strong focus across product categories. A key highlight includes Cetaphil activation, including reaching over 5 billion impressions globally through its campaigns for two events in the first quarter of 2024, with #FaceOfCetaphil campaign for the New York Fashion Week and the U.S. #GameTimeGlow campaign for the Super Bowl, along with locally tailored promotional activities such as the one for Chinese New Year. In addition, 2024 marks the celebration of 25 years of Sculptra, with activation initiated in the first quarter enabled by new scientific data and insights.

Finally, Galderma’s commitment to market-leading education and services was showcased through its presence at major medical congresses, including at the Aesthetic & Anti-Aging Medical World Congress (AMWC), the American Academy of Dermatology (AAD) annual meeting, and IMCAS World Congress. Engagement with healthcare professionals covered the full spectrum of Galderma’s portfolio, with a particular focus on showcasing its unparalleled aesthetics portfolio and yielding growing appreciation for nemolizumab. Galderma also launched ‘NEXT’, an innovative report that unveils the possible future of aesthetics, identifying six key trends with leading minds from the aesthetics community.

March 22, 2024, also marked an important milestone for Galderma, as its first trading day on the SIX Swiss Exchange, with 237,897,635 shares recorded in the commercial register following its Initial Public Offering (IPO). Galderma was internally already run as a public company prior to the listing, with robust governance, corporate platform, and regular external communications.

In particular, Environmental, Social and Governance (ESG) has been and will remain integral to the company’s strategy. To demonstrate this commitment, in 2024, Galderma engaged Sustainalytics to perform a broad-based pre-IPO Corporate ESG Assessment of Galderma, covering eight ESG categories, including Product Governance, Corporate Governance, Human Capital, Emissions, Effluents and Waste, and Business Ethics. Sustainalytics assessed Galderma as having an overall indicative Corporate ESG Assessment of 19.5, which places Galderma in the ‘low risk’ category as of February 23, 2024. The indicative score would place Galderma in the top fourth percentile of all companies in its subindustry assessed by Sustainalytics2.

Webcast details

Galderma will host a trading update call today at 14:00 CEST to discuss first quarter 2024 results and respond to questions from financial analysts. Investors and the public may access the webcast by registering on the Galderma Investor Relations website at https://investors.galderma.com/events-presentations.

Appendix – Net sales by product category and geography

In million USD

 

First quarter net sales

 

Year-on-year growth

 

2023

 

2024

 

Constant currency

 

Reported

Group total

 

954

 

1,071

 

12.4%

 

12.3%

By product category

 

 

 

 

 

 

 

 

Injectable Aesthetics

 

430

 

511

 

19.3%

 

18.8%

Neuromodulators

 

218

 

263

 

20.4%

 

20.5%

Fillers & Biostimulators

 

212

 

248

 

18.2%

 

17.0%

Dermatological Skincare

 

326

 

351

 

8.4%

 

7.9%

Therapeutic Dermatology

 

198

 

209

 

4.1%

 

5.2%

By geography

 

 

 

 

 

 

 

 

International

 

567

 

660

 

16.5%

 

16.3%

U.S.

 

387

 

411

 

6.4%

 

6.4%

 

责任编辑: admin

看新闻,关注新闻

天猫网友:紅塵悲歡惆悵
评论:结婚的日子我已经定好了,现在就差定新郎了。

猫扑网友:我會很愛你
评论:昔日迎风尿三丈、如今顺风尽湿鞋。

本网网友:忘記飛の蝶
评论:听说你过得不好,我坐在门口乐了一整天。

搜狐网友:㏒° 多情mmmm
评论:喜欢发呆的人,心里一定有另一个纯净的世界。

淘宝网友:一个2B的男人
评论:现代女生三从四得,三从:从不温柔,从不体贴,从不讲理;四得:惹不得,说不得,骂不得,打不得。

百度网友:身軆被我所用
评论:我是一个很有原则的人,我的原则只有三个字,看心情

凤凰网友:迷乱浮生ˉ2c1
评论:如果你看到面前的阴影,别怕,那是因为你的背后有阳光!

天涯网友:要堅持到最後
评论:下辈子做只考拉,每天睡觉20个小时,吃2个小时,发呆2 个小时,这就是完美人生啊。

网易网友:先森,你算个what
评论:令我感到骄傲和自豪的是,至今为止,地球仍被我踩在脚下。

其它网友:冷笑你的无知
评论:我也曾有过一双翅膀,不过我没用它在天上翱翔,而是放在锅里炖汤

相关阅读
分享到:
版权和免责申明

珠海都市网所有文字、图片、视频、音频等资料均来自互联网,不代表本站赞同其观点,本站亦不为其版权负责。相关作品的原创性、文中陈述文字以及内容数据庞杂本站无法一一核实,如果您发现本网站上有侵犯您的合法权益的内容,请联系我们,本网站将立即予以删除!